Riluzole prodrugs and their use
AssigneeBiohaven Therapeutics Ltd.
InventorsJay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
Claims4
A method for treating spinocerebellar ataxia in a subject in need of such treatment, comprising administering a riluzole prodrug to the subject, wherein said administration comprises:
- releasing an effective amount of riluzole or hydrate, solvate, pharmaceutically acceptable salt, or complex thereof into blood stream of the subject;
- and
- attenuating presynaptic glutamate release in the subject, and
- wherein the prodrug is a compound that is cleaved to release riluzole in the blood stream via either an enzymatic or general biophysical release process.
A method for treating spinocerebellar ataxia in a subject in need of such treatment, comprising administering a riluzole prodrug to the subject, wherein said administration comprises:
- contacting plasma of the subject with an effective amount of riluzole or hydrate, solvate, pharmaceutically acceptable salt, or complex thereof;
- and
- attenuating presynaptic glutamate release in the subject, and
- wherein the prodrug is a compound that is cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
Dependencies are inferred from the claim text.